Alivus Life Sciences quarterly results and financials

Alivus Life Sciences (ALIVUS)₹1,474−5.41%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (standalone), Alivus Life Sciences reported sales of ₹642 Cr, up 6.3% from Jun 2025, and net profit of ₹160 Cr, up 31.1% year on year. For the year to Mar 2026, sales were ₹2,562 Cr and net profit ₹566 Cr.

Sales (Jun 2026): ₹642 Cr
Net profit (Jun 2026): ₹160 Cr
Sales (FY Mar 2026): ₹2,562 Cr
Net profit (FY Mar 2026): ₹566 Cr
EPS (Jun 2026): ₹13.05
Borrowings (Mar 2026): ₹56.85 Cr

Company filings, standalone accounts; latest reported quarter Jun 2026

Alivus Life Sciences quarterly results

₹ crore unless stated; each column is a quarter.

Alivus Life Sciences Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	597	575	539	591	508	644	652	604	590	675	692	642
Expenses	428	400	395	429	372	451	451	430	409	441	475	428
Operating Profit	167	173	141	159	134	191	198	172	179	231	215	212
OPM %	28.0%	30.0%	26.0%	27.0%	27.0%	30.0%	31.0%	29.0%	30.0%	34.0%	31.0%	33.0%
Other Income	4.99	1.99	2.99	4.99	8.97	9.98	9.97	8.97	14.96	−11.98	22.94	21.95
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.99	0.99	0.99	0.99	0.99
Depreciation	12.97	12.98	14.96	13.97	14.98	14.96	15.98	16.97	17.96	19.97	19.98	20.95
Profit before tax	159	162	130	150	127	186	192	164	174	199	217	213
Tax %	25.0%	25.9%	23.9%	26.0%	24.9%	25.9%	25.9%	25.0%	24.9%	23.9%	24.9%	25.0%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−19.06	0.00	0.00
Net Profit	119	119	98.29	111	95.29	137	142	122	130	151	164	160
EPS (Rs)	9.70	9.70	8.00	9.11	7.79	11.19	11.59	9.92	10.59	12.26	13.26	13.05

Alivus Life Sciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Alivus Life Sciences Profit and loss
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0.00	889	1,542	1,893	2,130	2,167	2,289	2,394	2,562	2,599
Expenses	0.00	637	1,063	1,293	1,504	1,517	1,607	1,701	1,753	1,753
Operating Profit	0.00	249	474	593	618	644	676	685	798	838
OPM %	−4.0%	28.0%	31.0%	31.0%	29.0%	30.0%	30.0%	29.0%	31.0%	32.3%
Other Income	0.00	0.00	10.98	0.00	13.96	27.95	10.97	32.90	34.91	47.87
Interest	0.00	0.99	33.98	87.91	27.98	0.99	1.99	1.99	4.99	3.96
Depreciation	0.00	18.95	28.94	32.92	37.96	41.94	52.86	60.91	74.91	78.86
Profit before tax	0.00	229	422	472	567	631	633	656	753	802
Tax %	4,199.9%	14.0%	26.0%	24.9%	25.9%	26.0%	24.9%	25.9%	24.9%	—
Exceptional items	0.00	−1.01	−1.01	0.00	−1.01	0.00	−1.01	4.01	−19.05	−19.06
Net Profit	0.00	197	314	353	420	468	472	487	566	605
EPS (Rs)	−430.08	997.72	1,598.38	358.62	34.21	38.13	38.45	39.65	46.01	49.16
Dividend payout %	0.0%	0.0%	0.0%	0.0%	61.1%	110.1%	59.1%	13.1%	11.1%	—

Alivus Life Sciences balance sheet

₹ crore, at each year end.

Alivus Life Sciences Balance sheet
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.00	1.99	1.99	1.99	24.95	24.97	24.95	24.96	24.95
Reserves	−0.99	85.83	400	750	2,026	2,111	2,304	2,788	3,304
Borrowings	0.00	0.00	0.00	0.00	2.99	18.95	16.95	56.88	56.85
Other Liabilities	1.00	1,386	1,323	1,245	416	548	503	540	594
Total Liabilities	0.00	1,474	1,724	1,997	2,469	2,701	2,848	3,409	3,979
Fixed Assets	0.00	455	545	572	594	779	803	953	1,046
CWIP	0.00	79.77	10.97	13.97	91.69	61.86	106	102	272
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	477	778
Other Assets	0.00	940	1,169	1,411	1,784	1,862	1,939	1,877	1,881
Inventories	0.00	401	413	513	516	605	667	674	692
Trade receivables	0.00	449	640	621	674	808	766	971	1,074
Cash & equivalents	0.00	1.99	9.99	116	512	309	302	70.98	1.99
Total Assets	0.00	1,474	1,724	1,997	2,469	2,701	2,848	3,409	3,979

Alivus Life Sciences cash flow

₹ crore, for each year.

Alivus Life Sciences Cash flow
	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	9.96	194	386	595	305	412	390	562
Cash from investing activity	−9.01	−51.08	−69.08	−122	−147	−116	−617	−571
Cash from financing activity	0.99	−137	−214	−78.87	−388	−279	−5.99	−63.90
Net cash flow	1.99	7.98	106	396	−228	17.96	−230	−68.85
Capex	9.01	51.05	68.05	132	163	129	166	307
Free cash flow	0.99	144	322	466	143	285	226	259
CFO / OP %	14.0%	61.1%	84.1%	119.0%	71.0%	85.1%	81.1%	93.1%

Alivus Life Sciences ratios

Working-capital days and returns, by year.

Alivus Life Sciences Ratios
	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	45	186	153	121	117	137	123	149	154
Inventory days	162	441	227	214	185	224	251	237	237
Days payable	42	202	112	93	111	159	140	138	128
Cash conversion cycle	165	424	268	241	190	202	235	248	263
Working capital days	−2,060	−187	−38	11	148	175	187	200	305
ROCE %	—	528.9%	185.9%	96.9%	41.9%	29.9%	28.0%	24.9%	24.9%

Alivus Life Sciences: frequently asked questions

What are the latest quarterly results of Alivus Life Sciences?

For the Jun 2026 quarter, Alivus Life Sciences reported sales of ₹642 Cr, up 6.3% year on year and net profit of ₹160 Cr, up 31.1% year on year. The operating margin was 33.0%.

What is the annual revenue of Alivus Life Sciences?

Alivus Life Sciences' sales for the year to Mar 2026 were ₹2,562 Cr; over the last twelve months they were ₹2,599 Cr.

What is the net profit of Alivus Life Sciences?

Net profit for the year to Mar 2026 was ₹566 Cr, and ₹605 Cr over the last twelve months. Earnings per share over the same trailing period were ₹49.16.

How much debt does Alivus Life Sciences have?

Alivus Life Sciences reported borrowings of ₹56.85 Cr at Mar 2026, against cash and equivalents of ₹1.99 Cr.

What is the free cash flow of Alivus Life Sciences?

Cash from operations was ₹562 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹259 Cr.

Loading…